**Executive Summary**
Union Health Minister Shri J.P. Nadda reviewed the progress and initiatives of the Indian Pharmacopoeia Commission (IPC), commending their work in strengthening pharmacopoeial standards and pharmacovigilance. The Indian Pharmacopoeia is now recognized in 19 countries. The 10th edition of the Indian Pharmacopoeia 2026 is scheduled for launch in the first week of January 2026.
**Key Points / Main Content**
* **IPC Achievements and Commendations**
* IPC commended for strengthening pharmacopoeial standards and pharmacovigilance.
* IPC's efforts support the government's vision of Atmanirbhar Bharat and Viksit Bharat.
* Indian Pharmacopoeia recognized in 19 countries, enhancing India's regulatory credibility.
* IPC plays a pivotal role in ensuring medicine quality, safety, and efficacy.
* IPC remains a critical scientific and regulatory reference for medicine standards.
* **Future Initiatives and Goals**
* 10th edition of the Indian Pharmacopoeia 2026 to be launched in January 2026.
* Minister emphasized IPC’s crucial role in implementing the Pharmacovigilance Programme of India (PvPI).
* Minister appreciated IPC efforts to strengthen reporting systems and build capacity among healthcare professionals.
* IPC to continue focusing on innovation, digitalization, and global harmonization of standards.
* IPC reaffirms commitment to strengthen pharmacopoeial and pharmacovigilance standards and to enhance international collaboration.
**Impact Analysis**
**Indian Pharmacopoeia Commission (IPC)**
* **Impact:** The IPC is recognized for its role in bolstering pharmaceutical standards and pharmacovigilance. It is encouraged to continue its focus on innovation, digitalization, global harmonization and to strengthen indigenous scientific expertise.
* **Action Required:** Continue efforts in strengthening pharmacopoeial standards, enhancing international collaboration, innovation, and digitalization, and contributing to national and global health objectives.
**Healthcare Professionals**
* **Impact:** Directly involved in adverse drug reaction reporting and building capacity, thereby enhancing patient safety.
* **Action Required:** Strengthen reporting systems and build capacity regarding pharmacovigilance.
**Ministry of Health and Family Welfare**
* **Impact:** Responsible for the oversight and direction of the IPC. The review reflects the ministry's commitment to ensuring high healthcare standards.
* **Action Required:** Continue supporting and guiding the IPC in its various initiatives.
**Indian Public**
* **Impact:** Benefits from enhanced medicine quality, safety, and efficacy. The Indian Pharmacopoeia is a critical scientific and regulatory reference, ensuring uniform medicine standards across the country.
* **Action Required:** None mentioned.
Key Entities Referenced
Indian Pharmacopoeia Commission (IPC): Regulatory body responsible for setting pharmacopoeial standards in India.
Indian Pharmacopoeia: Official book of standards for drugs manufactured and/or marketed in India.
Pharmacovigilance Programme of India (PvPI): Programme to monitor adverse drug reactions and ensure patient safety.
Ministry of Health and Family Welfare: The government ministry responsible for health policy in India.
Ministry of Health and Family Welfare
Union Health Minister Shri J P Nadda reviews
progress and initiatives of the Indian
Pharmacopoeia Commission
Shri Nadda commends IPC’s continued efforts to strengthen
pharmacopoeial standards and pharmacovigilance,
supporting the Government’s vision of Atmanirbhar and Viksit
Bharat through self-reliance, scientific excellence, and strong
healthcare standards
The Indian Pharmacopoeia is now recognised in 19 countries,
reflecting growing international confidence in India’s
regulatory and scientific capabilities. This recognition
strengthens India’s position as the Pharmacy of the World
and underscores the credibility of Indian pharmacopoeial
standards globally: Shri Nadda
10th edition of the Indian Pharmacopoeia 2026 to be
launched by the Union Health Minister in the first week of
January 2026
प्रव तथ: 26 DEC 2025 5:50PM by PIB Delhi
Union Minister of Health and Family Welfare, Shri Jagat Prakash Nadda, today reviewed the progress and
initiatives of the Indian Pharmacopoeia Commission (IPC), in the presence of Ms. Nivedita Shukla Verma,
Secretary, Department of Chemicals and Petro-Chemicals (DoCP) and holding additional charge as
Secretary, MoHFW.Shri Nadda appreciated IPC’s sustained efforts in strengthening pharmacopoeial standards and
pharmacovigilance activities, which contribute to the Government’s vision of Atmanirbhar Bharat and a
Viksit Bharat, promoting self-reliance, scientific excellence, and robust healthcare standards.
During the review, Shri Nadda commended IPC for its pivotal role in ensuring the quality, safety, and
efficacy of medicines, thereby protecting public health. He noted that the Indian Pharmacopoeia remains a
critical scientific and regulatory reference, ensuring uniform standards of medicines across the country.
The Minister highlighted that “the Indian Pharmacopoeia is now recognised in 19 countries, reflecting
growing international confidence in India’s regulatory and scientific capabilities.” He observed that “this
recognition strengthens India’s position as the Pharmacy of the World and underscores the credibility of
Indian pharmacopoeial standards globally.”In addition to this, the 10th edition of the Indian Pharmacopoeia 2026 is scheduled to be launched by the
Union Health Minister in the first week of January, 2026.
In the meeting, Shri Nadda emphasized IPC’s crucial role in implementing the Pharmacovigilance
Programme of India (PvPI) to monitor adverse drug reactions and ensure patient safety, and appreciated its
efforts to strengthen reporting systems and build capacity among healthcare professionals. He also lauded
IPC’s contribution to Atmanirbhar Bharat through strengthening indigenous scientific expertise and
regulatory standards, while supporting global public health. The Minister encouraged IPC to continue
focusing on innovation, digitalisation, and global harmonisation of standards in line with the vision of
Viksit Bharat, to ensure universal access to safe and quality medicines.
The details of the activities were presented by Dr. V. Kalaiselvan, Secretary-cum-Scientific Director (IPC)
and he further reaffirmed the commitment to further strengthen pharmacopoeial and pharmacovigilance
standards, enhancing international collaboration and contributing to national and global health objectives.Shri Harsh Mangla, Joint Secretary, MoHFW and other senior officers of the Ministry were also present at
the meeting.
****
SR
HFW/HFM-IPC Review Meeting/26December2025/1
(रलीज़ आईडी: 2208908) आगंतुक पटल : 903
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही , Punjabi